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Abstract
Background: The liver X receptors (LXRs) are oxysterol sensing nuclear receptors with multiple effects on
metabolism and immune cells. However, the complete genome-wide cistrome of LXR in cells of human origin has
not yet been provided.
Results: We performed ChIP-seq in phorbol myristate acetate-differentiated THP-1 cells (macrophage-type) after
stimulation with the potent synthetic LXR ligand T0901317 (T09). Microarray gene expression analysis was
performed in the same cellular model. We identified 1357 genome-wide LXR locations (FDR < 1%), of which 526
were observed after T09 treatment. De novo analysis of LXR binding sequences identified a DR4-type element as
the major motif. On mRNA level T09 up-regulated 1258 genes and repressed 455 genes. Our results show that LXR
actions are focused on 112 genomic regions that contain up to 11 T09 target genes per region under the control
of highly stringent LXR binding sites with individual constellations for each region. We could confirm that LXR
controls lipid metabolism and transport and observed a strong association with apoptosis-related functions.
Conclusions: This first report on genome-wide binding of LXR in a human cell line provides new insights into the
transcriptional network of LXR and its target genes with their link to physiological processes, such as apoptosis.
The gene expression microarray and sequence data have been submitted collectively to the NCBI Gene Expression
Omnibus http://www.ncbi.nlm.nih.gov/geo under accession number GSE28319.
Background
The nuclear receptors liver X receptor (LXR) a and b
(encoded by the genes NR1H3 and NR1H2) are tran-
scription factors that act as sensors for oxidized choles-
terol (oxysterols) [1-3]. High expression levels of LXRa
in metabolic active tissues fit with the central role of the
receptor in lipid metabolism, while LXRb is more ubi-
quitously expressed [4]. Interestingly, both LXRs are
found in various cells of the immune system such as
macrophages, dendritic cells and lymphocytes, which
suggests an important function in the innate and adap-
tive immune response [5-7]. In macrophages the accu-
mulation of excess lipoprotein-derived cholesterol
activates LXR and triggers the induction of a
transcriptional program for cholesterol efflux, such as
ATP-binding cassette transporter (ABC) A1 (ABCA1)
and ABCG1, while in parallel the receptor transrepresses
inflammatory genes, such as inducible nitric oxide
synthase, interleukin 1b and monocyte chemotactic pro-
tein-1 [8-11].
Oxysterols and intermediates of the biosynthetic cho-
lesterol pathway have been identified as the natural
ligands for LXR, while T0901317 (T09) is a potent syn-
thetic LXR agonist with an EC50 of about 50 nM
[12,13]. LXRs bind to DNA as a heterodimer with the
nuclear receptor retinoid X receptor (RXR) on direct
repeats (DRs) of (A/G)GGTCA core binding motifs with
four intervening nucleotides (DR4) [14]. These DR4-
type response elements (REs) have been identified in the
regulatory regions of a number of primary LXR target
genes [15-17]. Recently, the first genome-wide views of
LXR binding were obtained in a murine macrophage
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cell line [18] and in mouse liver [19]. In the murine
macrophage study overexpressed biotin-tagged LXRb
was used for the chromatin immunoprecipitation
(ChIP), followed by massive parallel sequencing (ChIP-
Seq). De novo motif analysis identified DR4-type REs as
the most highly enriched binding sequence, but only
6.3% of the LXR peaks contained such a DR4-type RE.
Also motifs for the transcription factors PU.1 and AP-1
were co-enriched [18].
The ability of LXRs to integrate lipid metabolism and
immune functions places them in an ideal position to
tailor macrophage responses. Therefore, we performed a
genome-wide analysis of T09-induced LXR binding in
macrophage-type phorbol myristate acetate (PMA)-dif-
ferentiated THP-1 human monocytic leukemia cells by
ChIP-Seq using a highly specific anti-LXR antibody. In
total we identified 1357 chromosomal LXR binding loca-
tions, of which 526 were observed after the T09 treat-
ment. At the mRNA level the ligand induced 1258
genes and repressed 455 genes. We studied the LXR cis-
trome and identified LXR-enriched genomic regions as
well as individual LXR target genes. Binding of LXR is
focused on 112 genomic regions with individual constel-
lations of binding sites and target genes. We could con-
firm that LXR controls functions related to lipid
metabolism and observed a strong link to apoptosis.
Therefore, this first report on genome-wide binding of
LXR in a human cell line provides new insights into
LXR target genes and their link to physiological pro-
cesses, such as apoptosis.
Results
Genome-wide binding of LXR in a human macrophage-
type cell line
THP-1 human monocytic leukemia cells were treated
for 3 days with PMA to induce a human macrophage-
type model and subsequently treated for 60 min with
the potent synthetic LXR agonist T09 or vehicle DMSO.
ChIP assays were performed using an antibody specific
for LXRa and b (and non-specific IgG as negative con-
trol). The LXR antibody was successfully used in regular
ChIP assays [20,21] and also applied in a very recent
LXR ChIP-seq study in mouse liver [19]. Its specificity is
further demonstrated in Western blot analysis (see addi-
tional file 1: Figure S1), where the antibody recognizes
both LXRa and LXRb protein in liver from wild type
mice. LXRa is not recognized in LXRa-/- mice, LXRb is
not recognized in LXRb-/- mice and both LXR bands
disappear in the LXRab-/- mice. Furthermore, the anti-
body recognizes both human LXRa and LXRb when
they are overexpressed in HeLa cells. This indicates that
the antibody is specific to both mouse and human
LXRa and LXRb.
Purified chromatin samples were sequenced using a
Solexa GAII platform. In order to detect genomic LXR
binding locations, we used Bowtie software [22] for the
read sequence alignment and the MACS program [23]
for detection of statistically significant pileups of frag-
ments when comparing to IgG. The number and overlap
of detected LXR binding locations in and between the
T09- and vehicle-treated cells are shown in Figure 1A
(see additional file 2: Table S1 for all binding locations).
Since the use of a single criterion for the selection of a
representative peak set could be restrictive for the
further analysis, we considered three criteria, each with
different stringency.
The first high stringency criterion with false discovery
rate (FDR) < 1%, fold enrichment (FE) > 4 and raw P-
value < 10-10 showed a higher number of peaks in the
ligand-treated sample (151 peaks) than in the vehicle-
treated sample (137 peaks), suggesting that the ligand
slightly induces LXR binding among the high confidence
binding locations. Interestingly, the peaks of both T09-
and vehicle-treated samples were enriched to exon and
intron regions, but ligand treatment clearly increased
the density of LXR binding close to the transcription
start site (TSS) (see additional file 3: Figure S2). Due to
these very stringent criteria the total number of peaks is
not very high (202 peak locations), but they have pro-
portionally higher overlap between T09- and vehicle-
treated samples (42.6%) than the two following criteria
showing overlaps of only 28.1% and 19.4%.
The second stringency level using a single criterion of
a FDR < 1% increased the number of LXR binding sites
in the T09-treated sample to 526 peaks and even more
(1212 peaks) in the vehicle-treated sample. In total, this
represents 1357 LXR binding locations. Loosening the
stringency to FDR < 5% further increases the total num-
ber of LXR binding locations in the vehicle-treated sam-
ple (6903 peaks) compared to the ligand treatment
(2817 peaks). In general, ligand treatment seems to
increase the number of high confidence peaks and to
decrease the number of lower confidence peaks suggest-
ing that liganded LXR is focusing on a fewer number of
genomic binding sites of possibly increased importance.
We then applied the de novo motif detection tool
MEME [24] on the sequences within ± 100 bp of the
summits of the 1357 LXR peaks with a FDR < 1%. From
the top 10 results obtained with the TOMTOM tool
[25] in the T09-treated peaks, only one sequence motif
resembled a known transcription factor binding site
with similarity score E < 105. This motif has a MEME
score of E = 1.4 × 10-12 and the TOMTOM tool indi-
cated its high similarity to two DR4-type LXR consensus
matrices reported in the Transfac database (M00766
with E = 4.95 × 10-10 and M00647 with E = 1.60 × 10-8)
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Figure 1 Genome-wide LXR binding locations in a human macrophage-type cell line. A Overlap between LXR binding locations in T09-
and vehicle-treated human macrophage-type cells (THP-1 cells treated for 3 days with 20 nM PMA) under three different stringency criteria for
ChIP-Seq peak selection. The high stringency criterion is comprised of the thresholds for FDR < 1%, FE > 4 and raw P-value < 10-10, while the
two less stringent criteria were simply FDR < 1% and FDR < 5%. B De novo motif obtained using sequences for ChIP-Seq peaks with FDR < 1%
(± 100 bp from peak summits) and the corresponding Transfac motif obtained from the public TOMTOM tool [25]. C Genomic region of the LXR
target gene ABCA1 that is up-regulated (indicated by red color) by T09 treatment. Indicated are ChIP-Seq read alignment tracks for the IgG
control (gray), the T09-treated sample (red) and the vehicle-treated sample (blue). Under each sample track the arrows indicate LXR binding
locations of high stringency (red) or FDR < 1% (blue). Extra lanes indicate the location of LXR in homologous sequences of the mouse genome
as previously published [18], de novo LXR binding sites within the peak area and insulator barrier regions identified via CTCF binding sites
observed in CD4+ T cells [32].
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(Figure 1B). As a major difference, the first two nucleo-
tides of the spacer (positions 7 and 8) seem to form a
consensus “CT” in our matrix, whereas in the best
matching Transfac matrix these positions are not clearly
enriched. The motifs reported by MEME of the vehicle-
treated sample included several compositionally biased
hits and none of them could be recognized by
TOMTOM.
Further analysis of all 1357 peak sequences with FDR
< 1% using the matrix screening function of the regula-
tory sequence analysis tools (RSAT) web server [26]
showed that a site similar to the de novo derived DR4-
type RE or its version with spacer positions 7 and 8 set
equal to any nucleotide (see Methods for details) can be
found in 7.4% (39 of 526 peaks) of the T09-treated peak
set and in 7.2% (87 of 1212) of the vehicle-treated peak
set with similarity P < 10-4. When the similarity thresh-
old was reduced to P < 10-3 the number of DR4-type
REs could be increased to 42.6% and 41.3% in T09- and
vehicle-treated samples, respectively (data not shown).
Due to relatively low percentage of DR4-type REs, we
screened the high stringency LXR peak sequences for
the nuclear receptor half-site motif RGKTCA in a DR 0-
6, everted repeat (ER) 0-12 and inverted repeat (IR) 0-6
arrangement. This resulted in enrichment for DR1-,
DR4- and IR1-type REs in the T09-treated sample and
DR4- and ER9-type REs in the vehicle-treated sample
(see additional file 4: Figure S3). Direct LXR-RXR het-
erodimer binding to DR1- and ER9-type REs has not yet
been found, but it had been reported on an IR1-type RE
[27].
Screening of the LXR peak sequences with all 459
non-redundant JASPAR database matrices (JASPAR
core, version 10/2009), without DR4-type LXR RE
among them, resulted in the following five most fre-
quent motifs in the T09-treated sample (with similarity
P < 10-4): EWSR1-FLI1 (15.4%), KLF4 (13.7%), RREB1
(13.7%), SP1 (13.1%) and the DR1-type RE PPARG:RXR
(12.0%). In the vehicle-treated sample these were
EWSR1-FLI1 (17.6%), MYF (11.8%), SP1 (11.8%), RREB1
(11.7%) and SPIB (10.9%). Among the top motifs SPIB
represents a purine-rich ETS-type motif, which is also
recognized by the transcription factor PU.1, previously
found in the LXR ChIP-Seq analysis from the murine
macrophage cell line RAW264.7 [18]. The EWSR1-FLI1
matrix also represents a binding site for ETS-type tran-
scription factors with various functions, such as cell
cycle regulation and cell migration [28]. RREB1 is
known to relate to RAS-mediated cell differentiation
[29] and SP1 and KLF4 both represent binding sites for
KLF-family proteins, where KLF4 is known to drive the
differentiation of immune cells [30]. As the motif
PPARG:RXR was the fifth most frequent in the T09-
treated sample and the PPARG gene was also detected
as up-regulated with a FC = 1.4 in our microarray at 4
h, we decided to search peaks with FDR < 1% for motifs
PPARG::RXRA (DR1-type PPRE based on ChIP-Seq per-
formed in mouse with identifier MA0065.2) and PPARG
(Pal3-type PPRE based on Selex screening performed in
human with identifier MA0066.1), available in JASPAR.
These covered together 16.5% (87 of 526) of the T09-
treated and 14.3% (173 of 1212) of the vehicle-treated
peak set with a similarity P < 10-4. Interestingly, most of
the peaks containing a PPARg binding motif did not
contain any DR4-type RE motif (79 of 87 peaks (90.8%)
in the T09-treated and 162 of 173 peaks (93.6%) in the
vehicle-treated peak set). These results indicate that
some of the LXR peaks observed in ChIP-Seq data
could be explained by an indirect DNA binding of LXR
via other transcription factors, such as PPARg, or by
cooperative direct DNA binding of LXR together with
some of the mentioned transcription factors.
A large part (42.6%) of the LXR binding locations in
the high stringency set (Figure 1A) represent the well
understood case of LXR being present on its genomic
binding site both before and after the ligand treatment.
This is illustrated at the genomic region of the well-
known LXR target gene ABCA1 [31] showing four peaks
from the stringent set and one additional from the FDR
< 1% set (Figure 1C). This observation corroborates our
previous report of LXR binding sites on the ABCA1
gene by regular ChIP assays [20]. Moreover, of the five
sites observed at the ABCA1 gene, three contain DR4-
type REs and four correspond to those detected pre-
viously in the first mouse LXR ChIP-Seq study [18]. All
five peaks were also occupied by LXR in the absence of
ligand, but after T09 treatment the intensity of LXR
binding increased. Interestingly, the five LXR locations
and the ABCA1 TSS are contained within the same
block, which is flanked by CTCF binding sites (data
from in CD4+ T cells [32]) that are known as chromatin
barrier insulators. This suggests that this genomic region
displays the complete set of binding sites needed to
understand the LXR regulation of the ABCA1 gene.
In summary, depending on chosen stringency criteria
we detected in a human macrophage-type cell line
between 202 and 8139 genomic LXR binding sites. The
only identified de novo motif in the peak areas was a
DR4-type RE, but matrix screening also identified bind-
ing sites for other transcription factors, such as PPARg.
The example of the ABCA1 locus indicates that our
ChIP-Seq data can fully explain the LXR regulation of a
T09 target gene.
Spatial clusters of LXR binding locations and regulated
genes
Next we studied the genome-wide clustering of LXR
binding sites and the location of target genes within the
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clustered chromosomal regions with enrichment of
binding locations. We stimulated macrophage-type
PMA-treated THP-1 cells for 4 h with T09 or vehicle
(DMSO), extracted total RNA and analyzed it on Illu-
mina Human HT-12 v3 Expression BeadChip gene
expression microarrays. Statistical analysis detected 1713
regulated genes (P < 0.01), out of which 1258 were up
and 455 down-regulated (see additional file 5: Table
S2). The response already after 4 h suggests that these
genes are primary LXR target genes.
The genome-wide organization of the high stringency
set of 202 LXR binding locations (Figure 1A) and of the
1713 T09-regulated genes in their physical context is
shown in Figure 2 using window density based visualiza-
tion. This visualization shows the densities of ChIP-Seq
peaks and regulated genes across the genome within 1
Mb windows. The window densities are weighted by the
FEs of ChIP-Seq peaks and the log2 fold changes (FC) of
the differentially expressed (DE) genes, which empha-
sizes high peaks or extremely differentially expressed
genes. Subsequent analysis of the window density data
using segmentation (for details, see Methods) to detect
the exact borders of the peak-enriched regions resulted
in the indicated 112 distinct genomic areas. Regions
with ≥ 2 peaks and ≥ 3 T09-regulated genes are high-
lighted in red and listed in Table 1 (the complete list of
all regions with extended information is summarized in
additional file 6: Table S3).
Generally, the distribution of LXR binding locations in
the genome-wide view (Figure 2) correlates with the
density of all genes (r = 0.55) and slightly with the den-
sity of differentially expressed genes (r = 0.32), but the
number of LXR peaks in the 112 hotspots does not cor-
relate with the proportion of DE genes in these regions
nor with the density of DE genes in these regions (see
additional file 7: Figure S4). In a more detailed view, we
correlated each of the 112 hotspot regions with the
number of measured up-regulated (Figure 3A, left
panel) and down-regulated (Figure 3A, right panel)
genes with the number of expected up- or down-regu-
lated genes. Using a binomial test with threshold P
<0.05 to indicate statistical significance, we identified in
both groups several regions that contain an unexpected
high number of DE genes. Region R26 in chromosome
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Figure 2 Spatial genomic organization of LXR binding locations in relation to T09 target genes. The 202 LXR locations of the high
stringency peak set (Figure 1A) and the 1713 T09-regulated genes with adjusted P < 0.01 in 22 + X human chromosomes are visualized. A 1
Mb sliding window was used for the density graphs. These were further segmented, in order to detect chromosomal regions enriching LXR
binding locations. One hundred twelve genomic regions were identified as hotspots for LXR actions, of which those with ≥ 2 peaks and ≥ 3
regulated genes are highlighted in red.
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Table 1 Genome-wide hotspots of LXR action
Region
number
Region coordinates LXR sites Regulated
genes
Regulated gene names
Chr Location T09 vehicle Up Down
R1 1 8412456-
11763591
2 1 3 2 RP3-477M7.4, KIF1B, EXOSC10, RERE, ENO1
R3 1 23630263-
26071982
2 2 3 1 RPL11, PNRC2, CLIC4, HNRNPR
R4 1 27018838-
33511169
2 0 3 3 YTHDF2, SPOCD1, KHDRBS1, SLC9A1, PUM1, SNRNP40
R5 1 43282794-
47844512
2 2 6 3 ERMAP, MED8, POMGNT1, KIAA0494, STIL, CMPK1, GPBP1L1, TMEM69, MKNK1
R6 1 150237798-
154193105
1 2 8 2 MRPS21, MCL1, ENSA, GABPB2, S100A9, S100A8, RPS27, C1orf43, APH1A, PSMD4
R7 1 154934773-
156706753
1 3 4 2 GON4L, KIAA0907, SLC25A44, CCT3, SHC1, C1orf66
R8 1 201798268-
207228338
1 2 5 2 IPO9, UBE2T, KDM5B, TMEM183A, RBBP5, ADIPOR1, SOX13
R10 1 226626264-
229694443
4 4 4 0 RP11-118H4.1, FTHL2, SPHAR, ABCB10
R14 2 69240275-
73460367
0 2 5 2 ANTXR1, GFPT1, SNRNP27, MCEE, C2orf7, TEX261, RAB11FIP5
R20 3 127317065-
129041381
1 1 1 2 CNBP, MCM2, C3orf37
R21 3 193585240-
196669469
0 2 4 2 TM4SF19, AC092933.3, PAK2, NCBP2, TNK2, AC024937.4
R26 5 137273648-
140086267
2 2 6 5 FAM13B, BRD8, ETF1, MATR3, PURA, C5orf53, EGR1, C5orf32, PFDN1, HARS, ZMAT2
R28 5 175818220-
179780388
2 1 2 5 RP11-889L3.1, RNF130, PRELID1, HNRNPAB, RUFY1, CANX, GFPT2
R29 5 178977558-
180671711
2 0 1 3 RNF130, RUFY1, CANX, GFPT2
R34 6 166778406-
170893749
1 2 4 0 BRP44L, CCR6, PSMB1, PDCD2
R39 7 150069060-
151361890
1 2 2 2 GIMAP8, FASTK, GIMAP5, AGAP3
R45 8 143354160-
145736580
4 5 0 4 TOP1MT, PUF60, BOP1, MFSD3
R48 9 106856540-
108403400
4 4 3 0 SMC2, ABCA1, FKTN
R51 9 138541640-
140484943
7 9 1 2 EDF1, PMPCA, ZMYND19
R53 11 308106-911658 1 2 1 2 RPLP2, IFITM2, TMEM80
R56 11 63448921-
66445276
5 4 2 8 TRMT112, PRDX5, RTN3, GPR137, DPF2, SSSCA1, FIBP, DPP3, RBM4, RBM4B
R57 11 66247879-
70053509
1 2 1 4 FADD, DPP3, RBM4, RBM4B, SUV420H1
R59 11 118230301-
126138751
1 2 5 6 UBE4A, AP000926.1, TMEM218, EI24, RPUSD4, ATP5L, ARCN1, HINFP, SLC37A2,
FAM118B, SRPR
R61 12 56229243-
57628892
2 1 5 4 AC034102.1, CNPY2, PTGES3, NACA, PRIM1, MMP19, RAB5B, RNF41,CS
R75 16 108057-2759032 1 4 4 3 STUB1, FAHD1, NDUFB10, PDPK1, RHBDF1, AC141586.5, KCTD5
R76 16 2009518-3072385 3 1 3 2 NDUFB10, PDPK1, TNFRSF12A, AC141586.5, KCTD5
R77 16 28616902-
31394319
3 3 2 2 SULT1A1, VKORC1, QPRT, ITGAX
R80 17 3572089-7418491 3 0 5 1 TMEM93, ITGAE, MIS12, TXNDC17, ZBTB4, ACADVL
R83 17 41843489-
47502285
2 1 7 4 DUSP3, GJC1, KIAA1267, KPNB1, PNPO, ZNF652, AC004797.1, NMT1, NSF, CDK5RAP3,
NFE2L1
R84 17 55015562-
59147703
2 2 3 4 COIL, SRSF1, AC005884.1, SUPT4H1, TRIM37, DHX40, TMEM49
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5 (Figure 3B) and region R56 on chromosome 11 (Fig-
ure 3C) are examples of this type of analysis. Region
R26 contains six up- and five down-regulated genes and
two high stringency LXR locations present in both T09-
and vehicle-treated samples. The high stringency LXR
location close to the T09 target genes EGR1 (early
growth response protein) and ETF1 (eukaryotic transla-
tion termination factor 1) is shown in higher resolution
(Figure 3B). Region R56 contains eight down- and two
up-regulated genes and five high stringency LXR loca-
tions in the T09 sample and four in the DMSO sample,
two of which are overlapping. Here the region upstream
of the T09 target genes GPR137 (G protein-couple
receptor 137), TRMT112 (tRNA methyltransferase 11-2
homolog) and PRDX5 (peroxiredoxin 5) is shown in
higher resolution (Figure 3C).
However, there are also several differences in the loca-
tion of LXR binding sites and T09 target genes. One of
the most obvious differences is the differential expres-
sion of several genes on the X chromosome (Figure 2).
With the exception of region R112 located at the 3’ end
of the X chromosome no LXR binding location in
neither the high stringent nor in the FDR < 1% peak set
could be detected. These genes without any LXR bind-
ing locations nearby may either represent effects of T09
that are not mediated by LXR, secondary targets of LXR
or effects that are not visible in the ChIP-Seq dataset at
the investigated time point. It should be noted that T09
has been shown to be also a ligand of other nuclear
receptor superfamily members, such as farnesoid X
receptor [33], pregnane X receptor [34], retinoid acid
receptor-related orphan receptor [35] and androgen
receptor [36]. However, based on our microarray
analysis the genes encoding for farnesoid X receptor
and pregnane X receptor, NR1H4 and NR1I2, are not
expressed in PMA-differentiated THP-1 cells used in
this study.
Taken together, the genome-wide correlation of the
202 high stringency LXR locations with 1258 up-regu-
lated and 455 down-regulated T09 target genes indi-
cated 112 genomic hotspots for the actions of LXR.
Each of these hotspot regions provides a genomic sce-
nario, where up to seven LXR binding sites may explain
the regulation of up to eleven T09 target genes.
Identification of direct LXR target genes
In order to discriminate those T09 target genes that are
directly regulated by LXR compared to indirect LXR tar-
gets or no LXR targets at all, we examined the co-loca-
tion of LXR ChIP-Seq peaks with the TSS of DE genes
within proximal (0 to ± 100 kb) and distal (± 0.1 to ± 1
Mb) regions of peak summits (Figure 4A). For the prox-
imal regions we used the looser criterion with FDR <
5%, whereas for the distal region we used the more
stringent criterion FDR < 1%. From the 1713 DE T09
target genes 814 showed a LXR site within their proxi-
mal region and 799 a LXR peak within their distal
region, 550 of which are overlapping (Figure 4B). This
selection filtered out 38% (of which 85% were up-regu-
lated) of the T09-regulated genes resulting in 1063, 706
up-regulated and 357 down-regulated, more probable
direct LXR target genes (Figure 4C).
The 1063 genes with a LXR peak within 1 Mb of their
TSS are marked in the list of all T09 target genes (see
additional file 5: Table S2) and those that show an
adjusted P <0.001 for differential expression and a
Table 1 Genome-wide hotspots of LXR action (Continued)
R85 17 73512608-
76377808
2 1 3 3 C17orf95, SRSF2, BIRC5, TSEN54, RHBDF2, SEC14L1
R86 17 78863340-
80685893
5 4 4 5 ARL16, THOC4, SLC16A3, FN3KRP, AC127496.3, ACTG1, HGS, NARF, WDR45L
R93 19 17416476-
19617122
3 0 2 2 PDE4C, C19orf50, MRPL34, RFXANK
R95 19 39109721-
42789931
3 1 6 2 EIF3K, RPS16, EID2B, PSMC4, HNRNPUL1, RPS19, MRPS12, SERTAD3
R97 19 49298321-
51303301
3 0 0 3 BCAT2, BAX, VRK3
R98 19 52359054-
56499996
2 1 4 1 ZNF577, ZNF83, LILRB3, NLRP8, RPS9
R101 20 42939823-
48809213
2 2 6 3 YWHAB, DNTTIP1, UBE2C, NCOA3, B4GALT5, RNF114, SERINC3, TMEM189-UBE2V1,
CEBPB
R107 22 17618400-
22901769
1 1 4 7 BID, PI4KA, RANBP1, AC002472.8, CECR5, ATP6V1E1, BCL2L13, COMT, C22orf25,
XXbac-B33L19.3, PRAME
R108 22 22890122-
25024973
2 0 1 2 MIF, PRAME, GGT1
The genomic regions that contain two or more LXR binding sites and three or more T09-regulated genes (red in Figure 2). The locations of each region, the
number of LXR peaks and the number and name of the regulated genes are indicated (for a full summary of all regions and additional statistics see additional
file 6: Table S3).
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Figure 3 LXR peak regions enriched in DE genes. A Expected versus observed analysis of up- and down-regulated genes within the 112 LXR
peak regions. The linear regression line is shown in blue and the 95% confidence interval as grey area. Each data point represents one region
and is color-coded related to the number of LXR peaks it contains. Regions with a significantly (P < 0.05) enriched number of T09 target genes
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homologous sequences of the mouse genome as previously published [18], de novo LXR binding sites within the peak area and insulator barrier
regions identified via CTCF binding sites observed in CD4+ T cells [32]. C Example of region R56.
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proximal T09-induced LXR binding site are summarized
in Table 2. From this selection we show the locus of the
most up-regulated genes, NACA (nascent polypeptide-
associated complex alpha subunit), flanked by the
PTGES3 (prostaglandin E synthase 3) and PRIM1 (pri-
mase, DNA, polypeptide 1), which together form the
core of region R61 (Figure 4D). Another exemplified
locus is the most down-regulated gene, SLC3A2 (solute
Gene with distal peak (FDR < 1%)
Selected target genes
650
(38%)
1063
(62%)
with peak
without peak
T09 regulated 
genes
Gene with proximal peak (FDR < 5%) 650
(2659)
(3150)
(7187)
550
264 249
genes with
proximal peak
genes with
distal peak
+100 kb
TSS
+100 kb+1 Mb
TSS
-100 kb
-100 kb
A B C
de novo LXR
T09
DMSO
Heinz et al.
RefGene
chr12 (R61):
sig.
sig.
insulator
IgG
57,050 kb 57,100 kb
35-
0-
35-
0-
35-
0-
BAZ2A ATP5B PTGES3 NACA PRIM1
de novo LXR
T09
DMSO
Heinz et al.
RefGene
chr11 (R55):
sig.
sig.
insulator
IgG
62,640 kb
35-
0-
35-
0-
35-
0-
SNHG1 CHRM1SLC3A2
57,150 kb
62,680 kb
D
E
Figure 4 Filtering for direct LXR target genes. A Selection of target genes is based on LXR peaks with FDR < 5% within close (± 100 kb) or
with FDR < 1% within distant (± 0.1-1 Mb) regions from the T09 target gene TSS. B Numbers of all and DE genes (corrected P < 0.01) with a
LXR peak in the close or distant interval. C Selection of target genes based on the close and distant intervals and peak sets with FDR < 5% and
FDR < 1% stringencies, respectively, results in 1063 LXR target genes (62%) among the all 1713 DE genes. D The locus of the most up-regulated
gene NACA (based on the genes listed in Table 2) in region R61. Under each sample track the arrows indicate LXR binding locations of high
stringency (red), FDR < 1% (blue) or FDR < 5% (grey). Extra lanes indicate the location of LXR in homologous sequences of the mouse genome
as previously published [18], de novo LXR binding sites within the peak area and insulator barrier regions identified via CTCF binding sites
observed in CD4+ T cells [32]. E The locus of the most down-regulated gene SLC3A2 in region R55.
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carrier family 3A2), located in region R55 (Figure 4E). In
both examples there are dominant T09-induced tandem
LXR peaks controlling the respective region, i.e. both
the up-regulated (PTGES3, NACA and PRIM1) and the
down-regulated (SLC3A2) genes appear to follow the
same mechanism of a T09-induced LXR binding. In
addition, we made a comparison with the LXR locations
found previously in mouse macrophages [18] in a dis-
tance of 100 kb from the target gene TSS regions (see
additional file 5: Table S2). Among all 1713 differen-
tially expressed human genes only 7.9% (136 of 1713)
showed LXR binding in the corresponding mouse
region. Furthermore, among the 1063 selected target
genes only 9.9% (105 of 1063) contained an LXR peak
in the corresponding genomic region in mouse macro-
phages. Finally, from the human genes with proximal
LXR peaks (Table 2) 25.8% (8 of 31) of their mouse
homolog also showed LXR binding.
Next we compared altered expression of LXR target
genes to the occurrence of DR4-type REs within the
proximal LXR peaks (Figure 4A). Although DR4-type
REs with very high similarity scores are not very com-
mon (Figure 1B), they seem to be enriched to the peaks
in the vicinity of DE genes, especially when located
nearby up-regulated genes (Figure 5A). This is consis-
tent with the principal activation mechanism of LXR.
The six up-regulated genes ABCA1, ABCG1, SMPDL3A
(sphingomyelin phosphodiesterase, acid-like 3A),
NR1H3, SCD (stearoyl-CoA desaturase) and TATDN2
(TatD DNase domain containing 2) and the three down-
regulated genes CNNM4 (cyclin M4), HARS (histidyl-
tRNA synthetase) and PUF60 (poly-U binding splicing
Table 2 LXR target genes with peaks in proximal region
Gene expression data Peak within ± 100 kb Peak within
100 kb-1 Mb
Chr Start P-value Gene FC T09 vehicle Heinz et al. T09 vehicle
12 57094565 8.29E-05 NACA 5.63 S L S S
15 69745123 1.88E-04 RPLP1 5.19 M L L M
2 47272677 2.28E-04 CALM2 4.20 M M X L M
12 53689235 1.57E-04 PFDN5 3.59 S M L L
5 177482390 9.93E-04 LOC653314 3.20 M L S S
22 20103461 1.14E-04 RANBP1 3.17 S M M M
9 107543283 4.46E-04 ABCA1 2.94 S S X S S
21 43619799 8.29E-05 ABCG1 2.87 S S X L M
11 9681985 3.86E-04 LOC731640 2.79 S L M
4 154073494 3.16E-04 TRIM2 2.75 M M M M
11 64084167 6.49E-04 HSPC152 2.71 S M S S
16 2009519 5.19E-04 NDUFB10 2.70 M L S S
1 40306708 1.12E-04 TRIT1 2.44 M M M M
19 41768391 4.25E-04 HNRPUL1 2.37 S X S M
1 107599301 9.61E-05 PRMT6 2.25 M M
16 50352941 1.44E-04 BRD7 2.20 M M X L
9 128024073 5.65E-04 GAPVD1 2.02 M M M M
6 16129356 1.63E-04 MYLIP 2.00 M X
1 156163730 2.09E-04 SLC25A44 1.97 S S M S
1 228823162 5.41E-04 FTHL2 1.92 S S S S
5 137841784 7.92E-04 ETF1 1.91 S S L M
11 9685628 5.87E-04 SWAP70 1.86 S L M
19 12907634 5.28E-04 PRDX2 1.84 S L X L S
12 57057127 4.78E-04 PTGES3 1.76 S L S S
3 186507669 5.41E-04 RFC4 1.73 M M X L L
17 7362685 6.20E-04 ZBTB4 1.67 S L
1 109852192 7.41E-04 SORT1 0.60 M M M M
5 177631508 7.92E-04 HNRNPAB 0.59 S S M M
9 137208944 8.64E-04 RXRA 0.56 M M S M
3 57557090 9.67E-04 ARF4 0.55 S L M
11 62623518 1.88E-04 SLC3A2 0.43 S L S S
Only genes with a T09 peak with FDR < 1% within ± 100 kb from their TSS are displayed (the full list of LXR target genes is available in additional file 5: Table
S2). Symbols for peaks are as follows: S = stringent peak with FDR < 1%, FE > 4 and P < 10-10; M = peak with FDR < 1%; L = peak with FDR < 5%; X = any peak.
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factor 60 KDa) have LXR binding location with a motif
highly similar (P < 10-6) to a DR4-type RE. The ABCA1
gene is one of the best-known LXR target genes and
contains even three DR4-type REs within its regulatory
region (Figure 1C). Another example, the SMPDL3A
gene, carries two DR4-type REs within an LXR twin
peak very close to its TSS (Figure 5B). Using quantita-
tive real-time PCR (qPCR) and RNA from independently
performed stimulation experiments of PMA-differen-
tiated THP-1 cells with the synthetic LXR ligands T09
and GW3965 (GW), we validated nine representative
LXR targets genes: the known targets ABCA1, ABCG1,
MYLIP (myosin regulatory light chain interact), NR1H3
and SCD and the novel targets PPARG, SMPDL3A,
ADM (adrenomedullin) and ACSL3 (acyl-CoA synthe-
tase long-chain family member 3) (see additional file 8:
Figure S5). After 4 h of ligand treatment all nine genes
were significantly up-regulated by both LXR ligands.
In summary, 1063 of the 1713 T09 responding genes
are probable direct targets of LXR, since 77% of them
have at least one LXR binding site within 100 kb of
their TSS and the further 23% show at least one LXR
peak within 1 Mb distance. Interestingly, highly regu-
lated LXR target genes have a higher probability to con-
tain a DR4-type REs within the LXR peak associated
with these genes.
Association of functions to LXR target genes
In order to gain further insight into the possible com-
mon functions of the 1063 presumed direct LXR target
genes identified, we performed a functional annotation
analysis using the DAVID tool [37] and Gene Ontology
(GO) biological process terms. This resulted in 78 GO
terms with FDR < 5% mostly related to general themes,
such as metabolism, translation and RNA processing
(see additional file 9: Table S4). Among these, 71 genes
are related to regulation of programmed cell death (rank
42) and 73 genes to regulation of apoptosis (rank 53).
Interestingly, the immune-related terms are not
enriched significantly, as the best ranking immune-
related term “somatic diversification of immune recep-
tors via germline recombination” is only related to five
LXR target genes with FDR = 57.3%. We also analyzed
separately a more specific gene list, a subset of 1063
genes, with P < 0.001 for differential expression (Table
3). Also here we mostly found more general functions,
such as translation and RNA processing, and only two
terms related to lipid handling. None of the terms were
directly related to immune function but the two terms
“cellular response to stress” and “response to virus”
were detected. Separate analysis of genes with different
binding profiles of LXR in their vicinity (being present
either only in T09 samples, DMSO samples or both) did
not show any significant enrichment of additional path-
ways (data not shown). This suggests a homogeneous
function of LXR targets independent of possible differ-
ent regulatory mechanisms.
In order to detect the non-redundant sets of genes and
associated biological themes, we performed a clustering
analysis using enriched gene categories from the data-
bases GO, Kyoto Encyclopedia of Genes and Genomes
(KEGG), Reactome and CGAP tissue EST expression for
the 1063 true LXR target genes. In order to ease the
later inspection of results, we limited the number of
genes used in the clustering analysis to the 150 most
up-regulated and the 76 most down-regulated, preser-
ving the same ratio as between all 706 and 357 up- and
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Figure 5 LXR target genes with DR4-type REs. A Analysis of LXR
peak versus T09 target gene pairs by relating the log2 FC of target
genes with the similarity of the DR4-type REs within the closest LXR
peak (± 100 kb limit). For each peak, the gene with the smallest
expression P-value in that region is represented. Similarity is
indicated as -log10 of the P-value obtained from the RSAT motif
screening tool [26]. Pie diagrams on the top show the proportions
of differentially expressed gene-peak pairs among the all gene-peak
pairs within the similarity intervals 3-4.5, 4.5-6, 6-7.5, 7.5-9 and > 9.
In the DR4-type RE consensus sequence R = A or G, M = A or C,
and N any nucleotide. B Example region of the T09 target gene
SMPDL3A containing two DR4-type REs close to its TSS. Under each
sample track the arrows indicate LXR binding locations of high
stringency (red) or FDR < 5% (grey). Extra lanes indicate the location
of LXR in homologous sequences of the mouse genome as
previously published [18], de novo LXR binding sites within the peak
area and insulator barrier regions identified via CTCF binding sites
observed in CD4+ T cells [32].
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down-regulated LXR target genes. For the annotations,
we used all that were enriched with FDR < 50%, corre-
sponding to the raw P ≤ 0.036 in the GO enrichment
analysis. We were able to use this loose criterion and
obtain adequate data, because the clustering is robust to
false positive annotations. The genes and associated
annotations were clustered and visualized in parallel
using the heatmap.2 function available in the R-package
gplots [38]. Agglomerative hierarchical clustering with
an asymmetric binary distance measure was used by
treating each association between a gene and an annota-
tion as 1 and a lack of association as 0. This resulted in
eight visually homogeneous clusters of associated genes
and annotations (Figure 6): translation-related genes
(cluster 1), oxidation- and diabetes-related genes
expressed in liver (cluster 2), mRNA processing-related
genes (cluster 3), nitrogen metabolism-related genes
(cluster 4), programmed cell death regulation-related
genes (cluster 5), ubiquitin system genes with relation to
cell cycle and apoptosis (cluster 6), genes related to
intracellular transport including cholesterol transport
(cluster 7) and general ubiquitin system-related genes
(cluster 8).
Taken together, functional annotation analysis of the
1063 true LXR target genes using GO, KEGG, Reactome
and CGAP tissue EST expression databases resulted in
eight clusters, in which the functions apoptosis and lipid
transport are found, but no link to immune functions
were observed.
Discussion
This study provides the first genome-wide view of LXR
binding patterns in a human cell line using ChIP-Seq
assays. We performed this study in PMA-differentiated
THP-1 cells, a macrophage-type cellular system, which
increases our understanding not only of the well-known
role of LXR in lipid metabolism and transport, but also
the receptor’s assumed role in innate immunity and
other physiological processes.
The highly stringent analysis of the ChIP-Seq peaks
obtained from PMA-treated THP-1 cells after a 60 min
stimulation with the synthetic LXR ligand T09 or its
vehicle DMSO yielded a surprisingly low number of 202
genome-wide binding locations of the receptor. How-
ever, from the 151 LXR sites observed in the presence
of T09, 57% (86) are also bound in the absence of
ligand. This supports the canonical model for nuclear
receptor binding being valid for most members of the
superfamily [39]. According to this model the receptor
binds genomic DNA already in the absence of ligand,
probably in a complex with co-repressor and histone
deacetylase proteins, and locally represses the chromatin
structure. The addition of ligand induces a conforma-
tional change in the ligand-binding domain of the recep-
tor, which then leads to dissociation of the co-repressor
proteins and the recruitment of co-activators that open
chromatin structure. Alternatively, co-activators act as
mediators building a bridge to the basal transcription
machinery, which leads to the activation of RNA poly-
merase II and gene transcription. According to the data
presented here, this model seems to apply for a number
of known LXR binding sites close to target genes, such
as ABCA1.
A lower stringency in the detection of LXR ChIP-Seq
peaks increased the number of sites substantially, to a
total of 1357 (FDR < 1%) or even 8139 (FDR < 5%).
However, with this increase of putative LXR binding
sites the percentage of overlapping sites reduced to 28.1
and 19.4%, respectively, while the percentage of appar-
ent binding sites in the absence of ligand increased to
61.2 and 65.4%, respectively. We assume that most of
the latter sites are not genomic locations from which
LXR initiates gene activation, but rather unspecific con-
tact points of the genome with no functional impact.
Table 3 Enrichment analysis of high confidence LXR target genes
Term Count % P FE FDR
translation 16 6.56 9.14E-05 3.34 0.15
lipid biosynthetic process 15 6.15 2.48E-04 3.21 0.41
cellular response to stress 20 8.20 5.40E-04 2.44 0.89
RNA splicing 13 5.33 8.58E-04 3.16 1.41
response to virus 8 3.28 1.00E-03 5.07 1.64
positive regulation of gene-specific transcription 7 2.87 1.59E-03 5.55 2.60
RNA splicing, via trans-esterification reactions 9 3.69 1.68E-03 4.06 2.75
nuclear mRNA splicing, via spliceosome 9 3.69 1.68E-03 4.06 2.75
RNA splicing, via trans-esterification reactions with bulged adenosine as nucleophile 9 3.69 1.68E-03 4.06 2.75
RNA processing 18 7.38 2.41E-03 2.27 3.90
negative regulation of cholesterol storage 3 1.23 2.98E-03 34.51 4.82
The analysis was performed using the DAVID tool [37] for the specific set of LXR target genes with P < 0.001 for differential expression. GO biological process
terms with FDR < 5% are shown. Columns indicate the GO-term, its count and percentage in the target gene list, as well as the P-value, FE and FDR for the
enrichment.
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Figure 6 Co-functional modules of direct LXR target genes. Associations of LXR target genes with the annotations from Reactome, CGAP
tissue EST expression, KEGG and GO databases clustered and visualized using heatmap.2 function from R-package gplots [38]. The y-axis
columns indicate the annotations and x-axis rows the associated genes. Each association, depicted as a cell of the heat map, has been weighted
using the multiplication of log2 FC of a gene (row) and -log10 P-value of annotation (column) enrichment highlighting the most important
associations. Red and green color scales are used for up- and down-regulated genes, respectively. Both columns and rows have been clustered
using agglomerative hierarchical clustering with asymmetric binary distance measure. The eight gene and annotation clusters cover the majority
of the gene set. Indicated is also the LXR peak strength density graph, which summarizes the peak heights over the genes on the x-axis. For
each gene the peak strength has been calculated as a sum of the log2 FEs for the highest peak from the close (± 100 kb) and distant region (±
0.1 to ± 1 Mb).
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However, the tendency that ligand stimulation reduces
the number of sites to less than half (from 1212 to 526
and from 6903 to 2817) suggests that in its ligand-acti-
vated state LXR makes a more focused selection of
genomic targets.
Surprisingly, only 7.3% of the LXR peak summit
sequences contain a DR4-type RE, which, based on in
vitro studies, is the only high affinity DNA binding site
for LXR-RXR heterodimers. This fits with the observa-
tions of the two presently published mouse LXR ChIP-
Seq studies, where only 6.3% [18] or up to 8% [19] of
the LXR peaks contained a DR4-type RE. In a very
recent ChIP-on-chip report, 2035 LXRb-RXR binding
sites were identified within promoter regions of normal
human epidermal keratinocytes [40]. Although 1666
(82%) of these rather large genomic fragments contain a
kind of DR4-type RE, only 142 (7.0%) of them are highly
scored, resulting in a very similar percentage as in our
human and the mouse ChIP-Seq studies. For compari-
son, in our ChIP-Seq study on genomic vitamin D
receptor (VDR) locations in undifferentiated THP-1
cells [41], we found only 31% of the VDR peak summits
containing a VDR-specific DR3-type RE. We obtained
the same result also by a re-analysis of VDR ChIP-Seq
data from human lymphoblast cell lines [42,43]. These
observations indicate that either the binding specificity
of LXR (and VDR) is in the chromatin context far dif-
ferent than in in vitro assays (maybe due to cooperative
binding with other transcription factors, such as PPARg)
or LXR is not directly contacting DNA, but sits “piggy-
back” on another DNA-binding transcription factor.
Interestingly, in our T09 microarray the PPARG gene is
1.4-fold up-regulated, a value that was also confirmed
by qPCR with two different LXR ligands. In parallel, we
found for 16.5% of all LXR peaks in the T09-treated
sample a PPARg binding site. This suggests that PPARg
may be involved in the regulation of a subset of the
LXR target genes. Boergesen et al. reported very
recently that in mouse liver many genomic binding sites
of LXR are also bound by PPARa, which is the predo-
minant PPAR subtype in liver [19]. They suggest that
PPARa helps LXR in recognizing its preferred genomic
locations, a concept that may apply also for PPARg in
macrophages. Furthermore, Boergesen et al. also found
a higher percentage of DR1-type REs below their LXR
ChIP-Seq peaks than DR4-type REs, but in sum this can
explain only less than 25% of all LXR locations. There-
fore, they assume that both LXR and PPAR are far more
promiscuous in the recognition of their binding sites as
suggested by in vitro studies.
Nevertheless, we found DR4-type REs as functional
LXR binding sites in a number of prominent and highly
ligand-responsive LXR target genes, such as ABCA1,
ABCG1, NR1H3 and SCD. Moreover, in a reasonable
number of gene regulatory scenarios two or more geno-
mic LXR binding sites seem to work together in the reg-
ulation of a gene cluster (for example, NACA, GPR137
and their respective neighboring genes) or individual
genes (for example, ABCA1, SLC3A2 and SMPDL3A).
These multiple RE arrangements confirm observations
from single gene analyses with other nuclear receptors,
such as the VDR [44-46].
More important than the actual number of individual
LXR binding sites may be their spatial clustering along
the genome. We identified 112 genomic regions of an
average size of 1.7 Mb that contain clusters of highly
stringent LXR binding sites and up to 11 T09 target
genes. In total we identified 432 T09 target genes within
these genomic LXR hotspots. Although each of these
regions displays a rather individual arrangement of LXR
binding sites in relation to up- and down-regulated
genes, they seem to represent the core of the genome-
wide activities of LXR. However, 13 of the 112 regions
do not have any T09 target gene, suggesting that these
stringent LXR locations may have effects on more dis-
tant target genes.
In total our microarray analysis of the 4 h T09-stimu-
lated human macrophage-type cells lists 1713 genes,
73% of which are up-regulated, i.e. more than double as
many genes are up-regulated than down-regulated. Out
of these T09 target genes, 432 (25%) are found within
the 112 genomic LXR hotspots, 814 genes (48%) have
an LXR binding site within 100 kb distance from the
respective gene’s TSS and for a further 249 genes (15%)
an LXR location within 1 Mb of the TSS could be iden-
tified. This rate is similar to other reports comparing
ChIP-Seq and microarray results [42]. Nevertheless, this
raises the question about the regulation of the 650 T09
target genes without an LXR peak. These genes may be
secondary LXR targets. As only 15% of them are down-
regulated, a trans-repression mechanism is not very
likely.
Our study confirmed a number of known primary
LXR target genes, such as ABCA1, ABCG1, MYLIP,
NR1H3 and SCD, but we identified also a number of
previously unknown, novel LXR targets. The most up-
regulated LXR target gene, NACA, encodes for the nas-
cent polypeptide associated complex alpha protein,
which is associated to translation and protein folding
related processes and when depleted is responsible of
triggering endoplasmic reticulum stress-driven apoptosis
in hypoxic cells [47]. The PTGES3 gene, which is co-
located with the NACA gene, encodes for the co-chaper-
one protein prostaglandin E synthase 3 and is required
together with the primary chaperone proteins for proper
folding and functioning of the glucocorticoid receptor
and other steroid receptors [48]. The most down-regu-
lated gene, SLC3A2, is related to various processes, for
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instance in the migration of leukocytes from blood to
the central nervous system [49], but also to serum cho-
lesterol levels [50]. Also the SMPDL3A gene is an inter-
esting new LXR target, but it has not yet been well
characterized as there is only one report linking
SMPDL3A to bladder tumorigenesis [51].
LXR actions have been related to a number of autoim-
mune diseases, such as multiple sclerosis [52,53], rheu-
matoid arthritis [54,55] and experimental autoimmune
encephalomyelitis [56]. Interestingly, the association of
LXR with autoimmune and metabolic diseases is also
one of the major results of the annotation analysis of
the 1063 T09 responding genes that we consider as true
LXR target genes. The analysis showed the expected
relation to lipid metabolism and transport genes, but
did not provide any significant link to genes related to
innate immunity. However, the LXR regulation of
inflammatory cytokines is generally observed in experi-
mental settings, where lipopolysaccharide is used for sti-
mulation and where longer LXR ligand treatment times
are allowed [57]. Under these conditions inflammatory
cytokines are induced via the transcription factors AP1
and NF-B and can be inhibited via tethered LXR. In
this study, we used PMA for the differentiation of THP-
1 cells and T09 treatment of only 4 h. Interestingly,
under our experiment conditions, we observed a strong
association with apoptosis as more than 70 genes within
the 1063 candidates are related to this physiological pro-
cess. The link of LXRs to apoptosis has is already been
reported, not only in macrophages [58], but also in pan-
creatic b-cells [59] and different cancer cells [60,61].
Conclusion
We present here the first genome-wide view on LXR
locations in a human macrophage-type cellular system.
The core action of LXR is focused on 112 genomic hot-
spots that contain 432 target genes. In total 1063 of the
1713 LXR target genes can be explained by a direct
action of LXR, many of which have not been reported
before. These genes are related to lipid metabolism and
transport and to apoptosis, but not directly to immune
functions.
Methods
Cell culture
THP-1 human monocytic leukemia cells were grown in
RPMI 1640 supplemented with 10% fetal calf serum, 2
mM L-glutamine, 0.1 mg/ml streptomycin and 100 U/
ml penicillin and the cells were kept at 37°C in a humi-
dified 95% air/5% CO2 incubator. For differentiation
into macrophage-type cells the THP-1 cells were incu-
bated for 3 days with 20 nM PMA. Prior to stimulation
with 1 μM of the synthetic LXR ligands T09 or GW
(both from Sigma-Aldrich) or vehicle (dimethyl
sulfoxide (DMSO), final concentration 0.1%) the med-
ium was replaced by RPMI 1640 supplemented with 5%
lipid-depleted fetal calf serum, 2 mM L-glutamine, 0.1
mg/ml streptomycin and 100 U/ml penicillin and 20 nM
PMA.
Generation of LXR antibodies
Rat LXRa and LXRb proteins were purified as pre-
viously described [62]. Rabbits were immunized using a
standard immunization program at Agrisera (Vännäs,
Sweden). In brief, four injections with a total of 0.25 mg
of both LXRa and LXRb protein were performed and
serum was collected after 15 weeks. Purified LXRa and
LXRb proteins (1.4 mg) in 0.2 M NaHCO3, 0.5 M NaCl,
pH 8.3 buffer were coupled on a N-hydroxysuccinimide
activated matrix column and the immunized rabbit
serum was added to the column, which was washed
according to standard procedure. Elution of anti-LXR
antibody was performed in 10 cycles and all fractions
were pooled.
ChIP-seq
PMA-differentiated THP-1 cells (per condition nine 175
cm2 flasks, each 2 × 107 cells, density of 1 × 106 cells/
ml) were treated for 60 min with 1 μM T09 or vehicle
(DMSO). Then nuclear proteins were cross-linked to
DNA by adding formaldehyde directly to the medium to
a final concentration of 1% following incubation for 10
min at room temperature on a rocking platform. Cross-
linking was stopped by adding glycine to a final concen-
tration of 0.15 M and incubating at room temperature
for 10 min on a rocking platform. The cells were col-
lected by centrifugation and washed twice with ice cold
PBS (140 mM NaCl, 2.7 mM KCl, 1.5 mM KH2PO4, 8.1
mM Na2HPO4
.2H2O). Nuclear extraction was performed
by adding 500 μl PIPES buffer (5 mM Pipes pH 8.0, 85
mM KCl, 0.5% Nonidet P-40, protease inhibitors), incu-
bating for 10 min on ice and removing cytoplasmic
components by centrifugation. Nuclear pellets were dis-
solved in 500 μl SDS lysis buffer (1% SDS, 10 mM
EDTA, protease inhibitors, 50 mM Tris-HCl, pH 8.1)
and incubated 10 min on ice. Lysates were sonicated at
high power with 22 × 30 s pulses in a Bioruptor (Diage-
node, Liège, Belgium) to result in DNA fragments of
100 to 600 bp. Cellular debris were removed by centri-
fugation. Aliquots of 100 μl of the lysate were diluted
1:10 in ChIP dilution buffer (0.01% SDS, 1.1% Triton X-
100, 1.2 mM EDTA, 167 mM NaCl, protease inhibitors,
16.7 mM Tris-HCl, pH 8.1) and 2 μg of anti-LXR anti-
body [20] or non-specific anti-IgG rabbit (sc-2027, Santa
Cruz Biotechnologies, Santa Cruz, CA, USA) were
added and the samples were incubated for overnight at
4°C on a rotating platform. The immunocomplexes were
collected using 60 μl of BSA-coated protein A agarose
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bead slurry (Millipore) for 3 h at 4°C with rotation. The
beads were washed sequentially for 4 min in rotating
platform with 1 ml of the following buffers: low salt
wash buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA,
150 mM NaCl, 20 mM Tris-HCl, pH 8.1), high salt
wash buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA,
500 mM NaCl, 20 mM Tris-HCl, pH 8.1) and LiCl wash
buffer (0.25 M LiCl, 1% Nonidet P-40, 1% sodium deox-
ycholate, 1 mM EDTA, 10 mM Tris-HCl, pH 8.1).
Finally, the beads were washed twice with 1 ml TE buf-
fer (1 mM EDTA, 10 mM Tris-HCl, pH 8.0) and the
immune complexes were eluted twice using 200 μl elu-
tion buffer (1% SDS, 100 mM NaHCO3) for 15 min at
room temperature with rotation. The supernatants were
combined and the immune complexes were reverse
cross-linked overnight at 65°C in the presence of protei-
nase K (Fermentas) in a final concentration of 0.1 mg/
ml. DNA was extracted with the ChIP DNA Clean &
Concentrator Kit (Zymo Research Cooperation, HiSS
Diagnostics, Freiburg, Germany) according to manufac-
turer’s instructions and eluted in 40 μl nuclease-free
H2O. The ChIP templates were sequenced using a
Solexa Gene Analyzer II platform (Illumina) at 36 bp
read length using standard manufacturer protocols at
the Genomics Core Facility in Heidelberg, Germany.
ChIP-seq data analysis
Some of our following in-house bioinformatics tools
were already described recently [41,63]. Alignment of
sequence reads produced by T09-treated anti-LXR
immunoprecipitated sample, vehicle treated anti-LXR
immunoprecipitated sample and the IgG immunopreci-
pitated negative control sample against the reference
genome of version hg19 was done using Bowtie software
version 0.12.2 [22]. Command line arguments used with
Bowtie were: bowtie -n 1 -m 1 -e 70 -l 28 -k 1 -t -p 8 -q
-S –best hg19 input_file_name output_file_name. MACS
program version 1.3.7.1 [23] was used for finding statis-
tically significant peaks from the alignment sequences
using the following arguments: macs –pvalue = 1e-3
–nomodel –wig -t input_sample_file_name -c input_con-
trol_file_name –tsize = 36 –format = BAM –name =
analysis_topic –mfold = 13 –shiftsize = 250 –bw = 250
–verbose = 3. Subsequent refinement of MACS peaks
was done using the PeakSplitter program [64] with argu-
ments: PeakSplitter -p peak_folder_name -w aligne-
d_read_wig_folder_name -o output_folder -c 5 -v 0.6 -f.
An in-house R script was further used to calculate FEs,
P-values and FDR estimates for the found subpeaks
using an identical approach to MACS 1.3.7.1. Since
splitting the original peaks into several subpeaks may
produce large sets of weaker flanking residual peaks, dis-
torting for example the genomic and FE distributions of
the peaks, we kept for further analysis only those peaks
that either had FDR < 1% or were the best subpeak (by
FDR) within their parental MACS peak.
Further data analyses were conducted using an in-
house R pipeline containing tools for identifying peaks
overlapping in two samples, the analysis of genomic dis-
tribution of peaks and the integration of peak and gene
expression datasets. In the analysis of overlapping peaks,
we require that the narrower of the two overlapping
peaks shares at least 30% overlap with the broader peak.
Under these conditions also any weaker peak (still ful-
filling the criterion of raw P < 10-3 reported by the
MACS program) in one sample can have FDR < 5%,
FDR < 1% or high stringency peak sets, when the over-
lapping peak in the other sample fulfills the criterion.
Since many genomic positions cannot be uniquely
assigned to the selected 10 types of genomic elements
used in the analysis of peak distributions therein, in the
genomic element analysis a prioritization scheme was
employed, where the peaks were uniquely overlapped to
the elements in a step-wise exclusive scheme, starting
from coding elements (UTRs and coding exons), and
then moving to introns and outward from the gene.
For comparison with the ChIP-Seq data from a mouse
macrophage cell line [18] all peak coordinates from that
study were mapped to the human hg19 genome version
using Batch Coordinate Conversion tool available at the
UCSC Genome Browser [65].
Motif analysis
De novo analysis of LXR binding locations was per-
formed using stand alone version of MEME [24] on
sequences within ± 100 bp of the summits of the LXR
peaks. Peak sets with FDR < 1% and FDR < 5% with dif-
ferent FE cutoffs FE > 1, FE > 2 etc. from T09- and
vehicle-treated samples were analyzed separately in a
batch run. The analysis of peak sequences from the
T09-treated sample resulted in DR4-type REs in the top
10 of the MEME results with FDR < 1% peaks, when
using the cutoff FE > 2 (motif shown in Figure 1B) or
higher (tested until FE > 10). DR4-type REs could not
be detected, when similar de novo analysis for the peak
sequences obtained from the vehicle-treated sample or
all peak sequences with FDR < 5% from the T09-treated
sample were performed.
Identification of DR4-type REs within LXR peak
regions was performed using the RSAT matrix scan tool
available at http://rsat.ulb.ac.be/rsat[26]. Two matrices
were used as a model for a DR4-type RE: the de novo
detected matrix (Figure 1B) and the same matrix modi-
fied from the positions 7 and 8 within the spacer to
resemble more the DR4-type RE known in the literature.
The modification was made by setting at these positions
the frequency of any nucleotide equal (3). The analysis
of JASPAR matrices (JASPAR core, version 10/2009)
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was performed in similar manner. For the background
model, the input peak sequences were used to take into
account the nucleotide content within these regions.
Also for the analysis of DR-, ER- and IR-type REs the
RSAT dna-pattern tool was used. One mismatch was
allowed for an individual nuclear receptor binding site.
qPCR
Total RNA was extracted using High Pure RNA Isola-
tion kit (Roche). cDNA synthesis was performed using
Transcriptor First Strand cDNA Synthesis Kit (Roche),
using 1 μg of total RNA as a template and 50 pmol
oligo(dT)18 primers. qPCR was performed using a Light-
Cycler® 480 System (Roche). The reactions were per-
formed using 4 pmol of reverse and forward primers, 4
μl cDNA template and FastStart SYBR Green Master
(Roche) in a total volume of 10 μl. In the PCR reaction
the DNA templates were pre-denaturated at for 10 min
at 95°C, followed by amplification steps cycles of 20 s
denaturation at 95°C, 15 s annealing at primer specific
temperatures (see additional file 10: Table S5), 15 s
elongation at 72°C and a final elongation for 10 min at
72°C. PCR product quality was monitored using post-
PCR melt curve analysis. Fold inductions were calcu-
lated using the formula 2-(ΔΔCt), where ΔΔCt is ΔCt(sti-
mulus)-ΔCt(solvent), ΔCt is Ct(target gene)-Ct(contol
gene) and the Ct is the cycle, at which the threshold is
crossed. Relative expression levels of the target genes
were normalized to the internal control gene RPLP0.
Microarray analysis
Total RNA was checked for RNA integrity using a
Biorad Experion automated electrophoresis system
(Biorad, Nazareth, Belgium). None of the RNA samples
showed any sign of degradation. Triplicate samples were
analyzed with HumanHT-12 v3 Expression BeadChips
from Illumina (San Diego, CA, USA) at the Finnish
Microarray Centre (Turku, Finland). Raw data are avail-
able at GEO under accession GSE28319. Analyses of
microarray data were performed using R statistical soft-
ware version 2.11 [66] with associated libraries from
Bioconductor project version 2.6 [67]. Data were nor-
malized using VST transformation and RSN normaliza-
tion used as standard approach for Illumina arrays.
Normalized data were filtered in order to remove probes
without detected signal for any of the samples. Probe
sets that were not linked to any known or predicted
human gene were also filtered out. Linear Models for
Microarray Data (limma) package [68] using linear
model fitting for statistical testing with empirical Bayes
variance smoothing procedure was applied to detection
of differentially expressed genes. Obtained P-values were
corrected for multiple testing using the Benjamini &
Hochberg FDR procedure [69]. For downstream analysis,
GO [70] biological process terms were tested for
enrichment.
Spatial clustering of LXR binding locations
For the analysis of spatial clusters of LXR binding
locations we first performed a density analysis of geno-
mic coordinates of LXR peak summit locations in T09-
and vehicle-treated samples and the starting coordi-
nates of up- and down-regulated genes. This was made
using the standard R function “density” with a 1 Mb
size for the sliding window with 0.5 Mb steps over
each chromosome using the default Gaussian window
kernel function. The density values resulting from each
of these windows were weighted using FE values for
LXR binding locations or logarithmic FCs between
T09- and vehicle-treated samples for the locations of
regulated genes. In order to detect the exact borders of
the LXR hotspot regions, we performed a subsequent
clustering of the density data representing the LXR
binding locations by using methods developed origin-
ally for the analysis of array CGH data implemented in
R package SegClust [71,72]. First, the density vectors
representing LXR binding site distributions in T09-
and vehicle-treated samples were combined by taking
the maximum value for the two samples in each geno-
mic location. The resulting combined density data
were used for the “segmean” function, implemented in
SegClust, performing a dynamic programming-based
algorithm for finding the optimal breakpoints in terms
of changes of mean for a fixed number of breakpoints
K [72]. The method was applied using various K start-
ing from 1 ending to the number of analyzed data
points. The results were further used for the “segse-
lect” function, which uses an adaptive model selection
[71] between outcomes with different numbers of
breakpoints K. A result optimal in terms of this model
selection was chosen as representative for each chro-
mosome. The resulting chromosomal regions were
selected for containing at least one LXR binding loca-
tion within the high stringency set of peaks resulting
in 112 separate regions. The region borders were
widened 100 kb upstream of the 5’-border and 100 kb
downstream of the 3’-border of each region to cover
putative target genes in these regions.
Additional material
Additional file 1: Figure S1. Validation of LXR antibody. Protein
extracts from livers of WT, LXRa-/-, LXRb-/- and LXRab-/- mice [73] (A) or
from HeLa cells, which were transfected with the empty pSG5 expression
vector as control and pSG5 expressing human LXRa or LXRb,
respectively, using FuGENE 6 transfection reagent (Roche) (B), were
separated on 8% sodium dodecyl sulfate (SDS) polyacrylamide gels.
Western blotting using anti-LXR antibody was then performed using
standard procedures.
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Additional file 2: Table S1. LXR binding locations in a human
macrophage-type cell line. Columns indicate the chromosome, start
and end locations of ChIP-Seq peaks, peak length and summit, P-values
from Poisson distribution, FE in comparison to IgG, FDR value and
information on which sample peak was detected (T09- or vehicle-
treated). Information regarding to any peak present in both samples is
presented in two separate rows.
Additional file 3: Figure S2. Distribution of genomic LXR binding
sites to genomic elements. A Distribution of LXR binding locations
from the high stringent set of peaks to different genomic elements.
Unique peaks represent binding locations present only in one of the two
samples (disjoint areas of Venn diagram in Figure 1A) and in both
samples (joint set of Venn diagram in Figure 1A). B Distribution of peaks
around TSSs of closest genes.
Additional file 4: Figure S3. RE types present within the 202 high
stringency LXR peak set. Proportions of high stringency set of peaks
containing direct repeats (DRs), everted repeats (ERs) and inverted
repeats (IRs). Search has been made with RSAT DNA-pattern tool [26]
using RGKTCA half-site with indicated number of spacings.
Additional file 5: Table S2. Differentially expressed genes in a
human macrophage-type cell line. Columns indicate the chromosome,
start of the T09 target gene, log2 expression after T09- and vehicle-
treatment, adjusted P-value for gene expression difference, gene name
and FC. The detected LXR binding locations within proximal (± 100 kb)
and distal (± 1 Mb) area from the respective gene TSS are displayed on
the right side of the table.
Additional file 6: Table S3. Detailed information on all 112 LXR
hotspots. Numbers of peaks and genes are indicated similarly as in
Table 1. Additional columns indicate the tendency of each region having
vast majority (> 2 times) of peaks in T09- (or vehicle-) treated sample
versus vehicle- (or T09-) treated sample, the tendency of each region
having majority (> 2 times) of up- (or down-) regulated genes versus
down- (up-) regulated genes. Moreover, in separate columns up- and
down-regulated genes, number of all genes, gene density and enriched
GO terms (P < 0.05) are shown. Regions already shown in Table 1 are in
bold.
Additional file 7: Figure S4. Enrichment statistics of LXR binding
locations. The number of LXR peaks in one of the 112 hotspot regions
(Figure 2) is compared with the number of all genes (A), the number of
DE genes with adjusted P < 0.01 (B), the proportion of DE genes (C) and
the density of DE genes (D).
Additional file 8: Figure S5. LXR target gene validation. PMA-
differentiated THP-1 cells were treated for 4 h with vehicle (DMSO), 1 μM
GW3965 (GW) or 1 μM T0901317 (T09), total RNA was extracted and
qPCR was performed with primers specific for selected genes. The data
were normalized to the expression of the housekeeping gene RPLP0 and
fold inductions were calculated in reference to vehicle control. Columns
indicate the means of four independent cell treatments and the bars
represent standard deviations. Student’s t-test was performed to
determine the significance of the stimulation in reference to vehicle-
treated control (** P < 0.01; *** P < 0.001).
Additional file 9: Table S4. Enrichment analysis for all LXR target
genes. The analysis was performed using the DAVID tool [37] for all 1063
LXR target genes with P < 0.01 for differential expression. The columns
indicate GO identifier, term name, count of associated target genes and
the P-value and FDR for the enrichment.
Additional file 10: Table S5. qPCR primers used in the validation of
gene expression microarray results of select genes.
Abbreviations
ABC: ATP-binding cassette transporter; ACLS3: acyl-CoA synthetase long-
chain family member 3; ADM: adrenomedullin; ChIP: chromatin
immunoprecipitation; CNNM4: cyclin M4; DE: differentially expressed; DMSO:
dimethyl sulfoxide; DR4: direct repeat spaced by 4 nucleotides; EGR1: early
growth response protein; ER: everted repeat; ETF1: eukaryotic translation
termination factor 1; EWSR1: Ewing sarcoma breakpoint region 1; FDR: false
discovery rate; FLI1: friend leukemia virus integration 1; FE: fold enrichment;
GPR137: G protein-coupled receptor 137; GO: gene ontology; GW: GW3965;
HARS: histidyl-tRNA synthetase; IgG: immunoglobulin gamma; IR: inverted
repeat; KLF4: krüppel-like factor 4; LXR: liver X receptor; MYF: myogenic
factor; MYLIP: myosin regulatory light chain interact; NACA: nascent
polypeptide-associated complex alpha subunit; NR1H3: LXRα; PMA: phorbol
myristate acetate; PPAR: peroxisome proliferator-activated receptor; PRDX5:
peroxiredoxin 5, PRIM1, primase, DNA, polypeptide 1; PTGES3: prostaglandin
E synthase 3; PUF60: poly-U binding splicing factor 60 KDa; PWM: position
weight matrix; qPCR: quantitative real-time PCR; RE: response element;
RPLP0: ribosomal protein large P0; RREB1: Ras-responsive element-binding
protein 1; RSAT: regulatory sequence analysis tools; RXR: retinoid X receptor;
SCD: stearoyl-CoA desaturase; SCL3A2: solute carrier family 3A2; SMPDL3A:
sphingomyelin phosphodiesterase: acid-like 3A; SP1: Sp1 transcription factor;
SPIB: Spi-B transcription factor; T09: T0901317; TATDN2: TatD DNase domain
containing 2; TRMT112: tRNA methyltransferase 11-2 homolog; TSS:
transcription start site; VDR: vitamin D receptor.
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